NLRP3 & GSDMD Drug Pipeline — PatSnap Eureka
NLRP3, GSDMD & Pyroptosis Drug Pipeline: Inhibitor Strategies Across 15+ Inflammatory Diseases
The NLRP3 inflammasome–GSDMD axis is the most extensively studied mechanistic node in inflammasome-mediated cell death. Discover the full inhibitor landscape — from MCC950 to CRISPR gene editing — across atherosclerosis, Alzheimer's, IBD, sepsis, and beyond.
NLRP3 Drives Pathology Across 15 Distinct Disease Categories
The NLRP3 inflammasome–GSDMD axis is the most extensively studied mechanistic node in inflammasome-mediated cell death. NLRP3 is referenced as a driver of pathology across at least 15 distinct disease categories including atherosclerosis, Alzheimer's disease, type 2 diabetes, inflammatory bowel disease (IBD), sepsis, COVID-19, Duchenne muscular dystrophy, rheumatoid arthritis, acute pancreatitis, myocardial ischemia-reperfusion injury, stroke, retinal diseases, NAFLD/NASH, liver transplantation injury, and cryopyrin-associated periodic syndrome (CAPS).
At the molecular level, a two-step activation model is consistently described: (1) a priming signal — for example, LPS via NF-κB activation — that upregulates NLRP3, ASC, and pro-IL-1β transcription; and (2) an activating signal that triggers NLRP3 oligomerization, ASC speck formation, procaspase-1 recruitment and autocleavage, and downstream GSDMD cleavage.
Beyond the canonical caspase-1 pathway, non-canonical pyroptosis proceeds via caspase-11 (mouse) / caspase-4/5 (human) acting directly on GSDMD. Additional gasdermin family members — GSDMA, GSDMB, GSDMC, GSDME — are activated by caspase-3, caspase-8, and granzymes, substantially expanding the therapeutic target landscape. GSDME activation downstream of caspase-8 was specifically implicated in caspase-1/11-independent "incomplete pyroptosis" with selective IL-1α (but not IL-1β) release — a pharmacologically relevant distinction for drug candidates.
The PatSnap life sciences platform enables researchers to map this expanding target landscape across patent filings, clinical literature, and regulatory intelligence in a single workflow.
Pyroptosis Drug Pipeline: Modalities, Targets & Disease Coverage
Data derived from patent and literature analysis via PatSnap Eureka, representing a snapshot of innovation signals within the NLRP3–caspase-1–GSDMD axis.
NLRP3 Disease Coverage by Category
NLRP3 is implicated in at least 15 disease categories; cardiovascular/metabolic and inflammatory/autoimmune represent the broadest coverage in retrieved literature.
Therapeutic Modalities Targeting NLRP3–GSDMD Axis
Five distinct modality classes identified: small-molecule NLRP3 inhibitors represent the most therapeutically mature approach in the dataset.
Five Inhibitor Strategies Across the NLRP3–Caspase-1–GSDMD Pathway
Retrieved results document five distinct therapeutic modality classes, all at preclinical stages. MCC950 represents the most advanced characterized small molecule.
Direct NLRP3 Small-Molecule Inhibitors
MCC950 (CRID3), a diarylsulfonylurea, is the most extensively cited direct NLRP3 inhibitor. It targets the NACHT domain of wild-type NLRP3, preventing inflammasome assembly and caspase-1 activation. Oral administration in mdx mice for two months significantly reduced muscle pyroptosis, GSDMD expression, and disease pathology in Duchenne muscular dystrophy. QM380 and QM381 are first-in-class inhibitors specifically targeting NLRP3 PYD (pyrin domain) homo-oligomerization, demonstrating interference with ASC speck formation and reduced IL-1β release. Computational screening at the Icahn School of Medicine at Mount Sinai discovered novel NLRP3 and NLRC4 ATPase inhibitors with confirmed cell-based potency.
MCC950 · QM380/381 · INF4E · ATPase screening hitsDirect GSDMD Inhibitors
GSDMD is the preferred "final effector" target, offering broader anti-pyroptotic coverage than NLRP3-specific approaches because it acts downstream of multiple inflammasome types and caspases. Boston Children's Hospital / Harvard identified disulfiram (an FDA-approved alcohol addiction drug) and Bay 11-7082 as pyroptosis inhibitors that covalently modify the reactive cysteine C191 in human GSDMD to block pore formation — a compelling drug repurposing signal. PEITC (from cruciferous vegetables) directly inhibits GSDMD, reducing hepatocyte pyroptosis in acute liver injury models. WEHI researchers developed GSDMD-targeting nanobodies, resolving a crystal structure at 1.9 Å; three of six nanobodies inhibited pore formation in liposome leakage assays.
Disulfiram · PEITC · GSDMD nanobodies (WEHI)Natural Compound NLRP3 Inhibitors
An extensive body of work documents natural product-derived NLRP3 inhibitors. Corilagin inhibits NLRP3 via the ROS/TXNIP/NLRP3 pathway in gouty arthritis models. Astragaloside IV inhibits NLRP3-mediated pyroptosis via Nrf2 activation in cerebral ischemia-reperfusion injury. DHA and arachidonic acid reduce Kupffer cell pyroptosis by activating GPR120, which binds NLRP3 and prevents inflammasome complex assembly. Garlic chive-derived vesicle-like nanoparticles (GC-VLNs) demonstrate anti-NLRP3 activity in murine acute liver injury and obesity models. Approximately 40 natural compounds with anti-NLRP3 properties are catalogued in a University of Nebraska-Lincoln review.
Corilagin · Astragaloside IV · DHA/AA · GC-VLNs · PunicalinCRISPR/Cas9 NLRP3 Gene Editing
South China University of Technology researchers described a cationic lipid-assisted nanoparticle (CLAN) system delivering Cas9 mRNA and NLRP3-targeting guide RNA (CLANmCas9/gNLRP3) into macrophages. Intravenous injection mitigated LPS-induced septic shock, monosodium urate crystal-induced peritonitis, and improved insulin sensitivity in high-fat diet models. This represents the sole gene therapy modality identified in the dataset and is at a preclinical proof-of-concept stage. IP analytics platforms can help track CRISPR delivery IP as this field matures.
CLANmCas9/gNLRP3 · Sepsis · Peritonitis · ObesityMetabolic & Indirect Pathway Modulators
Several metabolic intermediates regulate NLRP3/pyroptosis. Fumarate was cited as an endogenous GSDMD-mediated pyroptosis inhibitor. Pyruvate dehydrogenase kinase (PDHK) inhibition significantly attenuates NLRP3 inflammasome activation in macrophages and septic mice by reversing metabolic reprogramming, enhancing autophagy, and reducing mitochondrial ROS. Disruption of glycolytic flux was identified as an endogenous NLRP3 activating signal via NADH depletion and mitochondrial ROS induction (Stanford University). Protein disulfide isomerase A1 (PDIA1) was identified as a pharmacologically targetable regulator of NLRP3 inflammasome assembly; the pro-drug AA147 inhibits NLRP3 activity in monocytes and macrophages. PPARγ agonists attenuate NLRP3-dependent IL-1β and IL-18 production by inhibiting NF-κB activation.
Fumarate · PDHK inhibition · AA147/PDIA1 · PPARγ agonistsKey Molecular Targets & Mechanistic Findings
From NLRP3's NACHT domain to GSDMD's reactive cysteine — mechanistic insights shaping drug design strategy.
NLRP3 — The Central Sensor
The single most cited target across retrieved results. NLRP3 assembles with ASC and procaspase-1 upon recognition of diverse PAMPs and DAMPs. Pharmacological inhibitor strategies target the NACHT domain (MCC950), the PYD domain (QM380/381), and the ATPase domain (computational screening hits). Gain-of-function mutations cause CAPS, with disease-associated mutants demonstrating altered sensitivity to MCC950. Nrf2 pathway activation was identified in multiple studies as a mechanism to suppress NLRP3 inflammasome priming.
GSDMD — The Terminal Effector
GSDMD's N-terminal domain inserts into the plasma membrane forming ~20 nm pores permitting IL-1β/IL-18 release and eventual cell lysis. A reactive cysteine residue (C191 in humans, C192 in mice) is a key drug target amenable to covalent modification by disulfiram and PEITC. Mathematical modeling demonstrated that reduction of GSDMD expression below a critical threshold switches cell death from pyroptosis to apoptosis — with a markedly higher threshold required compared to caspase-1 reduction. IRE-1α was identified as a modulator of GSDMD expression that switches cells between pyroptosis and necroptosis in liver pathology.
Translational Evidence: From Preclinical Models to Repurposing Opportunities
Retrieved results contain limited but specific translational signals. No approved drugs acting via direct NLRP3 or GSDMD inhibition, nor phase 2/3 clinical trial outcome data, are reported within this dataset.
| Compound / Approach | Target | Disease Context | Translational Signal | Stage |
|---|---|---|---|---|
| MCC950 (CRID3) | NLRP3 NACHT domain | CAPS; Duchenne muscular dystrophy | Oral dosing in mdx mice for 2 months; significant functional improvement; CAPS drug discovery interest noted | Advanced Preclinical |
| Disulfiram | GSDMD C191 cysteine | Broad pyroptosis inhibition | FDA-approved drug (alcohol use disorder); drug repurposing signal with accelerated translational path | Repurposing Signal |
| HNE (4-hydroxynonenal) | NLRP3 / Pyroptosis | Acute lung injury | Confirmed inhibition in human PBMCs (ex vivo) in addition to mouse macrophages — human translational evidence | Preclinical + Human PBMC |
| NLRP3 / GSDMD inhibitors | NLRP3; GSDMD | COVID-19 | Multiple papers identify NLRP3 and GSDMD as COVID-19 drug targets based on SARS-CoV-2-driven inflammasome activation evidence | Mechanistic Signal |
| CLANmCas9/gNLRP3 | NLRP3 gene (CRISPR) | Sepsis; peritonitis; obesity | IV injection mitigated LPS-induced septic shock, monosodium urate peritonitis, and improved insulin sensitivity in HFD mice | Proof of Concept |
Monitor the NLRP3 Clinical & IP Landscape in Real Time
PatSnap Eureka tracks patent filings, clinical signals, and literature across the full pyroptosis pipeline.
International Academic Innovation Network Driving Pyroptosis Drug Discovery
Innovation activity in this dataset is overwhelmingly literature-driven, with no patent filings appearing among retrieved records. The landscape is notably international and multi-institutional, spanning North America, Europe, and Asia-Pacific.
North American leaders include St. Jude Children's Research Hospital (Kanneganti laboratory — pyroptosis metabolic regulation), Boston Children's Hospital / Harvard Medical School (GSDMD cysteine-targeted inhibitors, NLRP3-NETosis nexus), Stanford University School of Medicine (glycolytic flux and NLRP3 activation), and the Icahn School of Medicine at Mount Sinai (computational NLRP3/NLRC4 ATPase inhibitor discovery).
European leaders include the University of Manchester (structural basis of NLRP3 signaling), Ghent University (MCC950 mechanism and CAPS mutant characterization), University of Oxford Kennedy Institute (posttranslational control of gasdermin-mediated pyroptosis in rheumatoid arthritis), and UCLouvain (MCC950 in Duchenne muscular dystrophy).
Asia-Pacific leaders include South China University of Technology (CRISPR/Cas9 NLRP3 editing via CLAN nanoparticles), Nanjing University (GSDMD inhibition by PEITC), The Walter and Eliza Hall Institute of Medical Research / WEHI in Australia (GSDMD nanobody inhibitors at 1.9 Å resolution), and Xiamen University (mathematical modeling of caspase-1/GSDMD switching). The PatSnap customer network includes leading research institutions across all these regions.
The absence of patent filings in the retrieved dataset is notable. The field is predominantly characterized by academic discovery research, with translation into IP-protected clinical candidates not captured in these records. PatSnap IP analytics can help identify where academic discoveries are transitioning into patent-protected programs. Key global IP bodies such as WIPO and the EPO provide additional filing data to complement literature signals.
NLRP3 Inhibitor Binding Domain & GSDMD Target Site Analysis
Structural and mechanistic characterization of key inhibitors across the NLRP3–GSDMD axis from retrieved academic literature.
NLRP3 Inhibitor Strategies by Binding Domain
Three distinct NLRP3 domains have been targeted pharmacologically: NACHT (MCC950), PYD (QM380/381), and ATPase (computational hits).
GSDMD Cysteine-Targeted Inhibitor Approaches
The reactive C191 cysteine in human GSDMD is the primary covalent drug handle; three distinct inhibitor classes have been characterized targeting this residue and adjacent epitopes.
NLRP3, GSDMD & Pyroptosis Drug Pipeline — key questions answered
Pyroptosis is a gasdermin-dependent, pro-inflammatory form of programmed cell death. Unlike apoptosis, pyroptosis is driven by inflammasome activation — particularly NLRP3 — leading to caspase-1 cleavage of GSDMD, pore formation in the plasma membrane, and release of pro-inflammatory cytokines IL-1β and IL-18. Mathematical modeling has shown that reducing GSDMD expression below a critical threshold can switch cell death from pyroptosis to apoptosis.
MCC950 (also designated CRID3) is a diarylsulfonylurea that potently targets the NACHT domain of wild-type NLRP3, preventing inflammasome assembly and caspase-1 activation. It is the most extensively cited direct NLRP3 inhibitor in the field. It has been studied in cryopyrin-associated periodic syndrome (CAPS) and Duchenne muscular dystrophy, where oral administration in mdx mice for two months significantly reduced muscle pyroptosis, GSDMD expression, and disease pathology.
GSDMD is the terminal effector of canonical (caspase-1) and non-canonical (caspase-4/5/11) pyroptosis. Its N-terminal domain inserts into the plasma membrane forming approximately 20 nm pores permitting IL-1β and IL-18 release and eventual cell lysis. A reactive cysteine residue (C191 in humans, C192 in mice) is a key drug target amenable to covalent modification. Disulfiram and PEITC have been shown to inhibit GSDMD by targeting this cysteine. Blocking GSDMD offers broader anti-pyroptotic coverage than NLRP3-specific approaches because it acts downstream of multiple inflammasome types and caspases.
NLRP3 is referenced as a driver of pathology across at least 15 distinct disease categories including atherosclerosis, Alzheimer's disease, type 2 diabetes, inflammatory bowel disease (IBD), sepsis, COVID-19, Duchenne muscular dystrophy, rheumatoid arthritis, acute pancreatitis, myocardial ischemia-reperfusion injury, stroke, retinal diseases, non-alcoholic fatty liver disease (NAFLD/NASH), liver transplantation injury, and cryopyrin-associated periodic syndrome (CAPS).
Yes. A landmark study from Boston Children's Hospital / Harvard identified disulfiram — an FDA-approved drug for alcohol use disorder — as a pyroptosis inhibitor acting by covalently modifying a reactive cysteine residue (C191 in human GSDMD) to block pore formation. This represents a drug repurposing signal with a potentially accelerated translational path.
South China University of Technology researchers described a cationic lipid-assisted nanoparticle (CLAN) system delivering Cas9 mRNA and NLRP3-targeting guide RNA (CLANmCas9/gNLRP3) into macrophages. Intravenous injection mitigated LPS-induced septic shock, monosodium urate crystal-induced peritonitis, and improved insulin sensitivity in high-fat diet models. This represents the sole gene therapy modality identified in the dataset and is at a preclinical proof-of-concept stage.
Still have questions? Let PatSnap Eureka answer them for you.
Ask PatSnap Eureka About NLRP3 & GSDMDAccelerate Your Pyroptosis & Inflammasome Drug Discovery
Join 18,000+ innovators already using PatSnap Eureka to map NLRP3, GSDMD, and caspase-1 inhibitor pipelines across 15+ inflammatory disease areas.
References
- University of Manchester — Structural basis of NLRP3 signaling and drug design; clinical potential of inflammasome inhibitors
- Sichuan Agricultural University — Mechanistic review of caspase-11 as LPS sensor driving non-canonical pyroptosis via GSDMD
- University of Melbourne — Gasdermin family members GSDMA, GSDMB, GSDMC, GSDME as pyroptotic executors
- GSDME activation downstream of caspase-8: incomplete pyroptosis with selective IL-1α release
- St. Jude Children's Research Hospital (Kanneganti lab) — NLRP3 responsiveness to DAMPs/PAMPs; NLRC4 inflammasome
- Ghent University — MCC950 mechanism of action; NACHT domain targeting; CAPS mutant characterization
- UCLouvain — MCC950 oral treatment in mdx mice for Duchenne muscular dystrophy; pyroptosis and GSDMD reduction
- Icahn School of Medicine at Mount Sinai — Computational discovery of NLRP3 and NLRC4 ATPase inhibitors
- Centro de Investigación Príncipe Felipe — QM380 and QM381 first-in-class NLRP3 PYD domain inhibitors; ASC speck interference
- University of Turin — INF4E cardioprotective NLRP3 inhibition in ex vivo myocardial I/R models
- Boston Children's Hospital / Harvard — Disulfiram and Bay 11-7082 as GSDMD C191 cysteine-targeting pyroptosis inhibitors
- Nanjing University — PEITC direct GSDMD inhibition; hepatocyte pyroptosis; acute liver injury ConA and CCl4 models
- WEHI Australia — GSDMD nanobody inhibitors; 1.9 Å crystal structure; steric pore blockade; 3 of 6 nanobodies active
- South China University of Technology — CLAN nanoparticle CRISPR/Cas9 NLRP3 gene editing; sepsis, peritonitis, obesity models
- University of Nebraska-Lincoln — Review of approximately 40 natural compounds with anti-NLRP3 properties
- Xiamen University — Mathematical modeling of caspase-1/GSDMD threshold switching between pyroptosis and apoptosis
- WIPO — World Intellectual Property Organization: global patent filing data
- EPO — European Patent Office: European patent landscape data
- NCBI / PubMed — National Center for Biotechnology Information: biomedical literature database
All data and statistics on this page are sourced from the references above and from PatSnap's proprietary innovation intelligence platform. This report is derived from a limited set of patent and literature records retrieved across targeted searches and represents a snapshot of innovation signals within this dataset only.
PatSnap Eureka searches patents and research to answer instantly.